{"shortAnswer":"GHRP-6 is on FDA's Category 2 list, and it is in no approved drug. No pharmacy or outsourcing facility has a legal route to make it. The evidence grade is limited-human: small studies show it raises growth hormone, but none tested it for muscle or recovery.","url":"https://peptideindex.ai/compound/ghrp-6","status":"category-2","statusCheckedAt":"2026-10-26T13:32:23.197Z","statusStale":false,"regulatoryAsOf":"2026-10-25","verified":"2026-10-26T13:32:23.237Z","primarySourceUrl":"https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks","clinicallyReviewed":false,"notice":"Information, not medical advice.","id":"92913334-e60a-4ade-81fa-58033d20f477","object":"compound","slug":"ghrp-6","name":"GHRP-6","attrs":{"name":"GHRP-6","class":"growth-hormone-axis","access":[{"type":"none","detail":"There is no legal route to GHRP-6 in the US today. It is in no approved drug, pharmacies may not use it, and every form is in Category 2 on FDA's outsourcing list.","source_url":"https://www.fda.gov/media/94164/download"}],"trials":[],"aliases":["growth hormone releasing peptide-6"],"summary":"A lab-made peptide that makes the body release growth hormone. Doctors have tested it to diagnose growth hormone shortage in adults.","citations":[{"n":1,"url":"https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks","tier":"primary","type":"regulatory","title":"FDA: bulk drug substances that may present significant safety risks, with GHRP-6 added in 2023"},{"n":2,"url":"https://www.fda.gov/media/94155/download","tier":"primary","type":"regulatory","title":"FDA: bulk drug substances nominated under section 503A, list updated 14 May 2026"},{"n":3,"url":"https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act","tier":"primary","type":"regulatory","title":"FDA: bulk drug substances used in compounding under section 503A"},{"n":4,"url":"https://www.fda.gov/media/94164/download","tier":"primary","type":"regulatory","title":"FDA: bulk drug substances nominated under section 503B, list updated 21 March 2025"},{"n":5,"url":"https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503b-fdc-act","tier":"primary","type":"regulatory","title":"FDA: bulk drug substances used in compounding under section 503B"},{"n":6,"url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/triad-rx-inc-569659-02052019","tier":"primary","type":"regulatory","title":"FDA warning letter to a compounding pharmacy that made drugs from GHRP-6, 5 February 2019"},{"n":7,"url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/tailor-made-compounding-llc-594743-04012020","tier":"primary","type":"regulatory","title":"FDA warning letter to a compounding pharmacy that made drugs from GHRP-6 and other peptides, 1 April 2020"},{"n":8,"url":"https://djholtlaw.com/navigating-the-2026-peptide-regulatory-landscape-federal-compliance-state-enforcement-and-the-legal-liabilities-of-healthcare-providers/","tier":"legal-analysis","type":"legal-analysis","title":"Holt Law: the 2026 federal rules on peptides and the risks for prescribers"},{"n":9,"url":"https://pubmed.ncbi.nlm.nih.gov/23099431/","tier":"peer-reviewed","type":"human-trial","title":"How GHRP-6 moves through the blood in nine healthy men, 2013"},{"n":10,"url":"https://pubmed.ncbi.nlm.nih.gov/9543138/","tier":"peer-reviewed","type":"human-trial","title":"GHRP-6 needs the body's own growth hormone-releasing hormone, in nine healthy men, 1998"},{"n":11,"url":"https://pubmed.ncbi.nlm.nih.gov/10583306/","tier":"peer-reviewed","type":"human-trial","title":"GHRP-6 and the steroid dexamethasone in healthy adults, 1999"},{"n":12,"url":"https://pubmed.ncbi.nlm.nih.gov/11980622/","tier":"peer-reviewed","type":"human-trial","title":"GHRP-6 as a test for growth hormone shortage in adult patients, 2002"},{"n":13,"url":"https://pubmed.ncbi.nlm.nih.gov/38873418/","tier":"peer-reviewed","type":"animal","title":"GHRP-6 and heart damage from the cancer drug doxorubicin in rats, 2024"},{"n":14,"url":"https://pubmed.ncbi.nlm.nih.gov/41901314/","tier":"peer-reviewed","type":"animal","title":"GHRP-6 after a heart attack model in rats, 2026"},{"n":15,"url":"https://pubmed.ncbi.nlm.nih.gov/16417467/","tier":"peer-reviewed","type":"animal","title":"GHRP-6 in a model of multiple organ failure and in gut cells, 2006"},{"n":16,"url":"https://pubmed.ncbi.nlm.nih.gov/22791951/","tier":"peer-reviewed","type":"animal","title":"GHRP-6 and stress damage to the stomach in rats, 2012"},{"n":17,"url":"https://pubmed.ncbi.nlm.nih.gov/7772238/","tier":"peer-reviewed","type":"in-vitro","title":"GHRP-6 in human pituitary tumor cells grown in a lab, 1995"},{"n":18,"url":"https://pubmed.ncbi.nlm.nih.gov/29864719/","tier":"peer-reviewed","type":"reference","title":"Doping labs test growth products sold outside legal channels and find Gly-GHRP-6, 2018"},{"n":19,"url":"https://pubmed.ncbi.nlm.nih.gov/42395176/","tier":"peer-reviewed","type":"reference","title":"Review: peptides sold to raise growth hormone, including GHRP-6, and their reported harms, 2026"},{"n":20,"url":"https://www.pharmacytimes.com/view/the-peptide-reclassification-everyone-s-talking-about-a-pharmacist-s-take-on-what-rfk-jr-s-announcement-actually-means","tier":"established-news","type":"reference","title":"Pharmacy Times: a pharmacist on the February 2026 peptide announcement"}],"known_risks":["FDA warns that compounded GHRP-6 may set off the immune system for some ways of taking it. The peptide can clump and carry impurities [^1].","FDA says the data it has show possible effects on cortisol, a stress hormone. They also show higher blood sugar, because the body responds less to insulin [^1].","A 2026 review lists harms in people who used peptides like GHRP-6 on their own. These include hormone and blood sugar changes, appetite changes, fluid build-up, muscle and joint pain, and skin reactions where the needle went in [^19].","A product sold as a growth peptide may hold something else. Doping labs found Gly-GHRP-6, a changed form with one extra amino acid, in growth products sold outside legal channels [^18]."],"short_answer":"GHRP-6 is on FDA's Category 2 list, and it is in no approved drug. No pharmacy or outsourcing facility has a legal route to make it. The evidence grade is limited-human: small studies show it raises growth hormone, but none tested it for muscle or recovery.","evidence_grade":"limited-human","open_questions":["None of the human studies we cite tested GHRP-6 for muscle or recovery in healthy people [^9] [^10] [^11] [^12].","A rise in growth hormone on a blood test is a lab marker. Nobody knows if that rise leads to the gains GHRP-6 is sold for [^10] [^19].","The heart and stomach results come from rats. Nobody knows if they hold in people [^13] [^14] [^16].","FDA says it has found little safety information on GHRP-6. Nobody knows what months or years of use do [^1]."],"section_routes":"There is no legal route to GHRP-6 in the US today [^1] [^4]. No approved drug contains it, and drugs made from it do not meet the rules for pharmacy compounding [^6]. Every form is in Category 2 on FDA's outsourcing list, so no outsourcing facility has a route either [^4] [^5].\n\nAny open trial would appear in the trials block below, with the date the official registry was last checked.","regulatory_as_of":"2026-10-25","section_channels":"Two ways of getting GHRP-6 show up in the records [^6] [^19]. The first is pharmacies that make it although the law does not allow it. FDA has sent warning letters to pharmacies that made drugs from GHRP-6 [^6] [^7]. One pharmacy told FDA it had dropped GHRP-6 from its products [^7].\n\nThe second is online sellers that market it as a research compound. A 2026 review says what these products hold, and how strong they are, is uncertain [^19]. Doping labs have found a changed form, Gly-GHRP-6, in growth products sold outside legal channels [^18]. Under federal law, a new drug may not be sold across state lines without FDA approval [^6]. GHRP-6 is in no approved drug [^6].\n\nFDA warns that compounded GHRP-6 may set off the immune system and may affect cortisol and blood sugar [^1].","section_evidence":"The evidence grade is limited-human: small studies in people show GHRP-6 raises growth hormone, but none tested the uses it is sold for [^10] [^11] [^12] [^19].\n\nIn nine healthy men, GHRP-6 given into a vein stayed in the blood for hours [^9]. Four of them had odd spikes of GHRP-6 as the body removed it [^9]. In nine other healthy men, a drug that blocks growth hormone-releasing hormone stopped most of the growth hormone rise from GHRP-6 [^10]. In 16 healthy adults, the steroid dexamethasone made that rise larger [^11]. In 20 adult patients, a GHRP-6 test picked out those short of growth hormone as well as a standard test did [^12]. The only problem seen in that study was flushing [^12].\n\nIn rats given the cancer drug doxorubicin, GHRP-6 protected the heart and other organs [^13]. In rats with a model of a heart attack, it reduced scarring and helped the heart pump [^14]. In rats under stress, it prevented stomach damage [^16]. In a model of organ failure, it reduced liver and gut damage, and the study summary does not name the species [^15]. In human pituitary tumor cells grown in a lab, it raised growth hormone release [^17]. These are animal and lab results, not results in people.\n\nA rise in growth hormone on a test is a lab marker. It does not show more muscle or faster recovery [^19]. A 2026 review says the benefits for sports and body shape are uncertain [^19].","regulatory_status":"category-2","section_what_it_is":"GHRP-6 is a lab-made chain of six amino acids [^9] [^17]. Amino acids are the building blocks of proteins. It makes the pituitary gland release growth hormone [^17]. That is a gland at the base of the brain. Most of its effect needs a hormone the body already makes, called growth hormone-releasing hormone [^10].\n\nDoctors have studied GHRP-6 as a test for growth hormone shortage in adults [^12]. Labs have also tested it for heart and gut injury in rats [^13] [^14] [^16]. Today GHRP-6 is sold online as a research compound for body shape and sports [^19].","section_is_it_legal":"GHRP-6 is on Category 2, FDA's list of substances that may present significant safety risks in compounding [^1]. That is FDA's view while it keeps reviewing, not a final rule, and it gives no compounder a legal route to make GHRP-6 [^5] [^6]. GHRP-6 is also in no FDA-approved drug [^6]. Checked 25 October 2026.\n\nFDA keeps lists for two kinds of compounders. A pharmacy is covered by section 503A of the law. An outsourcing facility is covered by section 503B [^3] [^5]. On FDA's outsourcing list of 21 March 2025, GHRP-6 is in Category 2 in every form [^4]. FDA added it on 29 September 2023 [^1]. FDA says it would consider acting against an outsourcing facility that makes drugs from a Category 2 substance [^5].\n\nOn FDA's pharmacy list of 14 May 2026, GHRP-6 is in Category 3 [^2]. That category holds substances nominated without enough support for FDA to review them [^2] [^3]. FDA has told pharmacies that drugs made from GHRP-6 do not meet the rules for pharmacy compounding [^6] [^7].\n\nGHRP-6 was studied as a test for growth hormone shortage [^12]. It is sold to build muscle and change body shape [^19]. A law firm and a pharmacy magazine expected it to stay restricted after a February 2026 federal announcement on peptides [^8] [^20].","unofficial_channels":[{"type":"compounding-outside-the-rules","what_it_is":"Made by a pharmacy from bulk GHRP-6 powder, although it does not meet the rules for pharmacy compounding.","enforcement":[{"date":"2019-02-05","text":"FDA warning letter to an Alabama compounding pharmacy that made drugs from GHRP-6.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/triad-rx-inc-569659-02052019"},{"date":"2020-04-01","text":"FDA warning letter to a Kentucky compounding pharmacy that made drugs from GHRP-6 and other peptides.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/tailor-made-compounding-llc-594743-04012020"}],"legal_position":{"text":"FDA says drugs made from GHRP-6 do not qualify for the compounding exemptions. It is in no approved drug and is not on the federal list.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/triad-rx-inc-569659-02052019"},"documented_risks":[{"text":"FDA warns that compounded GHRP-6 may set off the immune system for some ways of taking it, because the peptide can clump and carry impurities.","source_url":"https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks"},{"text":"FDA says the data it has show possible effects on cortisol and higher blood sugar.","source_url":"https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks"}]},{"type":"research-use-seller","what_it_is":"Sold online as a research compound, often to people seeking muscle or a change in body shape.","legal_position":{"text":"Under federal law, a new drug may not be sold across state lines without FDA approval. GHRP-6 is in no approved drug.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/triad-rx-inc-569659-02052019"},"documented_risks":[{"text":"A 2026 review says what these products hold, and how strong they are, is uncertain.","source_url":"https://pubmed.ncbi.nlm.nih.gov/42395176/"},{"text":"Doping labs found Gly-GHRP-6, a changed form with one extra amino acid, in growth products sold outside legal channels.","source_url":"https://pubmed.ncbi.nlm.nih.gov/29864719/"}]}]},"provenance":{"name":{"fact_id":"68acac23-2c08-4192-869b-50332aedc750","source_url":"https://pubmed.ncbi.nlm.nih.gov/23099431/","source_type":"peer-reviewed","captured_at":"2026-10-26T06:24:59.000Z","checked_at":"2026-10-26T13:32:23.217Z","confidence":1,"stale":false},"class":{"fact_id":"b563161c-a2d1-4dce-b646-8c698f953263","source_url":"https://pubmed.ncbi.nlm.nih.gov/9543138/","source_type":"peer-reviewed","captured_at":"2026-10-26T06:24:59.836Z","checked_at":"2026-10-26T13:32:23.220Z","confidence":1,"stale":false},"access":{"fact_id":"6918ab96-7805-4ac1-87cc-fb7d3f89cc9b","source_url":"https://www.fda.gov/media/94164/download","source_type":"primary","captured_at":"2026-10-26T06:06:48.104Z","checked_at":"2026-10-26T13:32:23.174Z","confidence":1,"stale":false},"trials":{"fact_id":"e5e9b644-d36c-4b4d-8869-53f09925c194","source_url":"https://clinicaltrials.gov/api/v2/studies?query.intr=GHRP-6&filter.overallStatus=RECRUITING%2CNOT_YET_RECRUITING&pageSize=50&sort=StartDate%3Adesc&countTotal=true&fields=NCTId%2CBriefTitle%2COverallStatus%2CPhase%2CLeadSponsorName%2CStartDate%2CLocationCountry%2CLocationState","source_type":"primary","captured_at":"2026-10-26T13:32:36.057Z","checked_at":"2026-10-26T13:32:36.057Z","confidence":1,"stale":false},"aliases":{"fact_id":"9bf6e40b-7974-4a76-8844-8402e2446e60","source_url":"https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks","source_type":"primary","captured_at":"2026-10-24T03:43:00.387Z","checked_at":"2026-10-26T13:32:23.184Z","confidence":1,"stale":false},"summary":{"fact_id":"d2d7afc0-bbb3-44b3-9d98-4d36a8eec95c","source_url":"https://pubmed.ncbi.nlm.nih.gov/11980622/","source_type":"peer-reviewed","captured_at":"2026-10-26T06:25:01.499Z","checked_at":"2026-10-26T13:32:23.206Z","confidence":1,"stale":false},"citations":{"fact_id":"93cd8ad2-e022-4f22-9598-fbe866b95928","source_url":"https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks","source_type":"primary","captured_at":"2026-10-24T03:43:00.387Z","checked_at":"2026-10-26T13:32:23.237Z","confidence":1,"stale":false},"known_risks":{"fact_id":"0a8dac37-7a7f-442f-807d-21593f183ef6","source_url":"https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks","source_type":"primary","captured_at":"2026-10-24T03:43:00.387Z","checked_at":"2026-10-26T13:32:23.227Z","confidence":1,"stale":false},"short_answer":{"fact_id":"7635c645-c5bd-40fa-abd7-467fa3324bd1","source_url":"https://peptideindex.ai/methodology#short-answer","source_type":"reference","captured_at":"2026-10-25T00:14:44.418Z","checked_at":"2026-10-26T13:32:23.223Z","confidence":1,"stale":false,"label":"our assessment"},"evidence_grade":{"fact_id":"39dec020-26c7-4cc3-8b29-3f87bacfac9d","source_url":"https://peptideindex.ai/methodology#evidence-grade","source_type":"reference","captured_at":"2026-10-25T00:14:45.193Z","checked_at":"2026-10-26T13:32:23.225Z","confidence":1,"stale":false,"label":"our assessment"},"open_questions":{"fact_id":"770115dc-a17f-42b4-aa8f-8f7aeca46e7d","source_url":"https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks","source_type":"primary","captured_at":"2026-10-24T03:43:00.387Z","checked_at":"2026-10-26T13:32:23.189Z","confidence":1,"stale":false},"section_routes":{"fact_id":"6a97707e-566e-48e8-8023-00b5d820a056","source_url":"https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks","source_type":"primary","captured_at":"2026-10-24T03:43:00.387Z","checked_at":"2026-10-26T13:32:23.235Z","confidence":1,"stale":false},"regulatory_as_of":{"fact_id":"b153e4d2-52c2-4185-ac5b-d2ee5b8de25b","source_url":"https://www.fda.gov/media/94164/download","source_type":"primary","captured_at":"2026-10-26T06:06:48.104Z","checked_at":"2026-10-26T13:32:23.194Z","confidence":1,"stale":false},"section_channels":{"fact_id":"a18a5157-4395-4582-a617-7ebe15e64781","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/triad-rx-inc-569659-02052019","source_type":"primary","captured_at":"2026-10-26T06:05:14.747Z","checked_at":"2026-10-26T13:32:23.201Z","confidence":1,"stale":false},"section_evidence":{"fact_id":"5d27cc7a-844b-4689-8a3e-c2d85412b7c0","source_url":"https://pubmed.ncbi.nlm.nih.gov/42395176/","source_type":"peer-reviewed","captured_at":"2026-10-26T06:06:56.272Z","checked_at":"2026-10-26T13:32:23.233Z","confidence":1,"stale":false},"regulatory_status":{"fact_id":"2a777cbf-e917-48b5-b301-ecff2d27cc02","source_url":"https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks","source_type":"primary","captured_at":"2026-10-24T03:43:00.387Z","checked_at":"2026-10-26T13:32:23.197Z","confidence":1,"stale":false},"section_what_it_is":{"fact_id":"6b9b7a95-d099-4458-94d8-6ae21b1698ce","source_url":"https://pubmed.ncbi.nlm.nih.gov/23099431/","source_type":"peer-reviewed","captured_at":"2026-10-26T06:24:59.000Z","checked_at":"2026-10-26T13:32:23.229Z","confidence":1,"stale":false},"section_is_it_legal":{"fact_id":"02082f3d-e153-4ef3-9f8d-ef251853fdde","source_url":"https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks","source_type":"primary","captured_at":"2026-10-24T03:43:00.387Z","checked_at":"2026-10-26T13:32:23.231Z","confidence":1,"stale":false},"unofficial_channels":{"fact_id":"3565ed95-ed9b-40de-819a-a3b88d0fcf48","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/triad-rx-inc-569659-02052019","source_type":"primary","captured_at":"2026-10-26T06:05:14.747Z","checked_at":"2026-10-26T13:32:23.214Z","confidence":1,"stale":false}},"citationsBySection":{"known_risks":[{"n":1,"title":"FDA: bulk drug substances that may present significant safety risks, with GHRP-6 added in 2023","url":"https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks"},{"n":19,"title":"Review: peptides sold to raise growth hormone, including GHRP-6, and their reported harms, 2026","url":"https://pubmed.ncbi.nlm.nih.gov/42395176/"},{"n":18,"title":"Doping labs test growth products sold outside legal channels and find Gly-GHRP-6, 2018","url":"https://pubmed.ncbi.nlm.nih.gov/29864719/"}],"open_questions":[{"n":9,"title":"How GHRP-6 moves through the blood in nine healthy men, 2013","url":"https://pubmed.ncbi.nlm.nih.gov/23099431/"},{"n":10,"title":"GHRP-6 needs the body's own growth hormone-releasing hormone, in nine healthy men, 1998","url":"https://pubmed.ncbi.nlm.nih.gov/9543138/"},{"n":11,"title":"GHRP-6 and the steroid dexamethasone in healthy adults, 1999","url":"https://pubmed.ncbi.nlm.nih.gov/10583306/"},{"n":12,"title":"GHRP-6 as a test for growth hormone shortage in adult patients, 2002","url":"https://pubmed.ncbi.nlm.nih.gov/11980622/"},{"n":19,"title":"Review: peptides sold to raise growth hormone, including GHRP-6, and their reported harms, 2026","url":"https://pubmed.ncbi.nlm.nih.gov/42395176/"},{"n":13,"title":"GHRP-6 and heart damage from the cancer drug doxorubicin in rats, 2024","url":"https://pubmed.ncbi.nlm.nih.gov/38873418/"},{"n":14,"title":"GHRP-6 after a heart attack model in rats, 2026","url":"https://pubmed.ncbi.nlm.nih.gov/41901314/"},{"n":16,"title":"GHRP-6 and stress damage to the stomach in rats, 2012","url":"https://pubmed.ncbi.nlm.nih.gov/22791951/"},{"n":1,"title":"FDA: bulk drug substances that may present significant safety risks, with GHRP-6 added in 2023","url":"https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks"}],"section_routes":[{"n":1,"title":"FDA: bulk drug substances that may present significant safety risks, with GHRP-6 added in 2023","url":"https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks"},{"n":4,"title":"FDA: bulk drug substances nominated under section 503B, list updated 21 March 2025","url":"https://www.fda.gov/media/94164/download"},{"n":6,"title":"FDA warning letter to a compounding pharmacy that made drugs from GHRP-6, 5 February 2019","url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/triad-rx-inc-569659-02052019"},{"n":5,"title":"FDA: bulk drug substances used in compounding under section 503B","url":"https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503b-fdc-act"}],"section_channels":[{"n":6,"title":"FDA warning letter to a compounding pharmacy that made drugs from GHRP-6, 5 February 2019","url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/triad-rx-inc-569659-02052019"},{"n":19,"title":"Review: peptides sold to raise growth hormone, including GHRP-6, and their reported harms, 2026","url":"https://pubmed.ncbi.nlm.nih.gov/42395176/"},{"n":7,"title":"FDA warning letter to a compounding pharmacy that made drugs from GHRP-6 and other peptides, 1 April 2020","url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/tailor-made-compounding-llc-594743-04012020"},{"n":18,"title":"Doping labs test growth products sold outside legal channels and find Gly-GHRP-6, 2018","url":"https://pubmed.ncbi.nlm.nih.gov/29864719/"},{"n":1,"title":"FDA: bulk drug substances that may present significant safety risks, with GHRP-6 added in 2023","url":"https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks"}],"section_evidence":[{"n":10,"title":"GHRP-6 needs the body's own growth hormone-releasing hormone, in nine healthy men, 1998","url":"https://pubmed.ncbi.nlm.nih.gov/9543138/"},{"n":11,"title":"GHRP-6 and the steroid dexamethasone in healthy adults, 1999","url":"https://pubmed.ncbi.nlm.nih.gov/10583306/"},{"n":12,"title":"GHRP-6 as a test for growth hormone shortage in adult patients, 2002","url":"https://pubmed.ncbi.nlm.nih.gov/11980622/"},{"n":19,"title":"Review: peptides sold to raise growth hormone, including GHRP-6, and their reported harms, 2026","url":"https://pubmed.ncbi.nlm.nih.gov/42395176/"},{"n":9,"title":"How GHRP-6 moves through the blood in nine healthy men, 2013","url":"https://pubmed.ncbi.nlm.nih.gov/23099431/"},{"n":13,"title":"GHRP-6 and heart damage from the cancer drug doxorubicin in rats, 2024","url":"https://pubmed.ncbi.nlm.nih.gov/38873418/"},{"n":14,"title":"GHRP-6 after a heart attack model in rats, 2026","url":"https://pubmed.ncbi.nlm.nih.gov/41901314/"},{"n":16,"title":"GHRP-6 and stress damage to the stomach in rats, 2012","url":"https://pubmed.ncbi.nlm.nih.gov/22791951/"},{"n":15,"title":"GHRP-6 in a model of multiple organ failure and in gut cells, 2006","url":"https://pubmed.ncbi.nlm.nih.gov/16417467/"},{"n":17,"title":"GHRP-6 in human pituitary tumor cells grown in a lab, 1995","url":"https://pubmed.ncbi.nlm.nih.gov/7772238/"}],"section_what_it_is":[{"n":9,"title":"How GHRP-6 moves through the blood in nine healthy men, 2013","url":"https://pubmed.ncbi.nlm.nih.gov/23099431/"},{"n":17,"title":"GHRP-6 in human pituitary tumor cells grown in a lab, 1995","url":"https://pubmed.ncbi.nlm.nih.gov/7772238/"},{"n":10,"title":"GHRP-6 needs the body's own growth hormone-releasing hormone, in nine healthy men, 1998","url":"https://pubmed.ncbi.nlm.nih.gov/9543138/"},{"n":12,"title":"GHRP-6 as a test for growth hormone shortage in adult patients, 2002","url":"https://pubmed.ncbi.nlm.nih.gov/11980622/"},{"n":13,"title":"GHRP-6 and heart damage from the cancer drug doxorubicin in rats, 2024","url":"https://pubmed.ncbi.nlm.nih.gov/38873418/"},{"n":14,"title":"GHRP-6 after a heart attack model in rats, 2026","url":"https://pubmed.ncbi.nlm.nih.gov/41901314/"},{"n":16,"title":"GHRP-6 and stress damage to the stomach in rats, 2012","url":"https://pubmed.ncbi.nlm.nih.gov/22791951/"},{"n":19,"title":"Review: peptides sold to raise growth hormone, including GHRP-6, and their reported harms, 2026","url":"https://pubmed.ncbi.nlm.nih.gov/42395176/"}],"section_is_it_legal":[{"n":1,"title":"FDA: bulk drug substances that may present significant safety risks, with GHRP-6 added in 2023","url":"https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks"},{"n":5,"title":"FDA: bulk drug substances used in compounding under section 503B","url":"https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503b-fdc-act"},{"n":6,"title":"FDA warning letter to a compounding pharmacy that made drugs from GHRP-6, 5 February 2019","url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/triad-rx-inc-569659-02052019"},{"n":3,"title":"FDA: bulk drug substances used in compounding under section 503A","url":"https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act"},{"n":4,"title":"FDA: bulk drug substances nominated under section 503B, list updated 21 March 2025","url":"https://www.fda.gov/media/94164/download"},{"n":2,"title":"FDA: bulk drug substances nominated under section 503A, list updated 14 May 2026","url":"https://www.fda.gov/media/94155/download"},{"n":7,"title":"FDA warning letter to a compounding pharmacy that made drugs from GHRP-6 and other peptides, 1 April 2020","url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/tailor-made-compounding-llc-594743-04012020"},{"n":12,"title":"GHRP-6 as a test for growth hormone shortage in adult patients, 2002","url":"https://pubmed.ncbi.nlm.nih.gov/11980622/"},{"n":19,"title":"Review: peptides sold to raise growth hormone, including GHRP-6, and their reported harms, 2026","url":"https://pubmed.ncbi.nlm.nih.gov/42395176/"},{"n":8,"title":"Holt Law: the 2026 federal rules on peptides and the risks for prescribers","url":"https://djholtlaw.com/navigating-the-2026-peptide-regulatory-landscape-federal-compliance-state-enforcement-and-the-legal-liabilities-of-healthcare-providers/"},{"n":20,"title":"Pharmacy Times: a pharmacist on the February 2026 peptide announcement","url":"https://www.pharmacytimes.com/view/the-peptide-reclassification-everyone-s-talking-about-a-pharmacist-s-take-on-what-rfk-jr-s-announcement-actually-means"}]},"channelsOpener":"This section describes what happens and is not a recommendation.","sources":["https://clinicaltrials.gov/api/v2/studies?query.intr=GHRP-6&filter.overallStatus=RECRUITING%2CNOT_YET_RECRUITING&pageSize=50&sort=StartDate%3Adesc&countTotal=true&fields=NCTId%2CBriefTitle%2COverallStatus%2CPhase%2CLeadSponsorName%2CStartDate%2CLocationCountry%2CLocationState","https://peptideindex.ai/methodology#evidence-grade","https://peptideindex.ai/methodology#short-answer","https://pubmed.ncbi.nlm.nih.gov/11980622/","https://pubmed.ncbi.nlm.nih.gov/23099431/","https://pubmed.ncbi.nlm.nih.gov/42395176/","https://pubmed.ncbi.nlm.nih.gov/9543138/","https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks","https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/triad-rx-inc-569659-02052019","https://www.fda.gov/media/94164/download"],"verified_at":"2026-10-26T13:32:23.237Z","published_at":"2026-10-26T13:49:24.994Z","parent":null,"children":[],"snapshots":{"trials":{"snapshot_at":"2026-10-26T13:32:36.057Z","stale":false,"notice":"A listing is not a recommendation. Trials have strict eligibility rules. Talk to your doctor and read the official record."}}}